Navigation Links
AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
Date:8/3/2009

QUEBEC CITY, Aug. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), its partner and licensee for perifosine in the North American market, has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for the Company's PI3K/Akt pathway inhibitor compound, perifosine (KRX-0401), in relapsed or relapsed/refractory multiple myeloma patients previously treated with bortezomib (VELCADE(R)). The SPA provides agreement that the Phase 3 study design adequately addresses objectives in support of a regulatory submission. The study, entitled, "A Phase 3 Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib", will be a double-blind, placebo-controlled study comparing the efficacy and safety of perifosine vs. placebo when combined with bortezomib and dexamethasone. The trial, powered at 90%, will enroll approximately 400 patients with relapsed or relapsed/refractory multiple myeloma. The primary endpoint is progression-free survival and secondary endpoints include overall response rate, overall survival and safety.

Juergen Engel, Ph. D., President and Chief Executive Officer of AEterna Zentaris commented, "We are very pleased and excited about perifosine moving forward into a Phase 3 trial. This represents a major milestone in our oncology drug development strategy which could hold great promise for patients with multiple myeloma."

About the Phase 3 Trial De
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
2. AEterna Zentaris Receives US$10 Million from Institutional Investors
3. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
4. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
5. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
6. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
7. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
8. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
9. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
10. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
11. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
(Date:12/15/2014)... YORK , Dec. 15, 2014  GlassesOff Inc. ... Yuval Bar-Gil as an independent director of the ... founder of AeroScout and served as its CEO until ... in 2012, a $240 million transaction. Recognized as the ... Mr. Bar-Gil,s leadership, AeroScout provided Wi-Fi -based RFID solutions ...
(Date:12/13/2014)... Clarassance, a privately held clinical-stage biotechnology company based ... Therapeutics , Inc. The new name is derived from ... in the lungs similar to branches on a tree), ... therapeutics for the treatment of respiratory diseases. , ... to mark the company's escalation into the clinical phase ...
(Date:12/13/2014)... December 13, 2014 QuickSTAT is making ... and Cold Chain capabilities, and is delighted to announce ... France, to serve Life Science clients in the region. ... a controlled-ambient warehouse, will provide 24/7 transportation and logistics ... investigational drugs, patient-clinical specimens, API, following IATA rules and ...
Breaking Biology Technology:Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2
... America, Inc.  (OTC Bulletin Board: CBAI ) announced ... www.bancovida.com ) to offer umbilical cord blood collection services in ... will allow BancoVida and Cord Blood America to educate prospective ... of storing their baby,s umbilical cord blood.  The stem cells ...
... 26, 2011 Infrared Systems International (OTCBB: IFRS) announces ... strategies for continued success. Most recently, the ... its subsidiary, Infrared Applications, Inc. (IAI).  The distribution marks ... from one engaged in the aerospace industry to one ...
... Shire plc (LSE: SHP, NASDAQ: SHPGY ... U.S. Food and Drug Administration (FDA) has granted marketing approval ... attacks of hereditary angioedema (HAE) in adults 18 years of ... challenges gaining rapid access to acute treatment such as the ...
Cached Biology Technology:Cord Blood America Enters Agreement With BancoVida, a Cord Blood Collection Company in San Juan, Puerto Rico 2Infrared Systems International Reflects on Past and Looks Forward to the Future 2Infrared Systems International Reflects on Past and Looks Forward to the Future 3FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 2FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 3FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 4FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 5FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 6
(Date:11/21/2014)... REDMOND, Wash. , Nov. 20, 2014 ... access for the Internet of Things (IoT), today announced ... position of chief operating officer. Previously a strategic advisor ... marketing, finance, and operations. Mr. Traynor is based out ... . He reports to Chris Muench , ...
(Date:11/18/2014)... , Nov. 17, 2014   ... EMC collaborate to develop The Partners Data Lake, ... The Partners Data Lake will allow researcher and ... diagnostics, treatment and the lives of patients ... and clinical activities across the Partners system, breaking ...
(Date:11/15/2014)... 13, 2014  While we may still be a few ... in "Star Trek" to gain instant access to all that ... with smartphones and tablets for monitoring and measuring our health ... This may seem a tad Orwellian to some, but a ... of these technological opportunities into their healthcare regime. ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... missing flu virus. When the flu isnt making people sick, ... Earth, it reappears in the appropriate season and starts its ... it hibernate, lying dormant in a few people and preparing ... Northern hemisphere to the Southern hemisphere and back, following the ...
... Researchers have discovered the secrets to enhancing youth ... 3-year study entitled Greener Voices proves that children ... responsibility for decisionmaking and planning. Childrens gardens ... are popping up in schools, communities, public venues, ...
... in Spanish . Breaking up the dosage ... of wheat and limits its negative effects on the environment. ... of the Basque Country (UPV-EHU) researcher, Teresa Fuentes Mendizbal, presented ... Wheat yields have increased over the decades, more concretely during ...
Cached Biology News:Tracking influenza's every movement 2Children's gardens mushrooming 2Dosage of fertilizer helps to enhance quality of wheat 2Dosage of fertilizer helps to enhance quality of wheat 3
Human TFPI Affinity Purified Polyclonal Ab Protein Family: Coagulation, Inflammation, Serine Protease Regulators...
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Eppendorf tube holder, for Tube rack 175 x 12 mm, 100. Category: Chromatography Systems & Accessories, Systems....
Pooled normal sreum with 0.1% sodium azide as preservative...
Biology Products: